CDMO
/cdmo

Sofgen Pharma, formerly Procaps Group, S.A., is an integrated healthcare and pharmaceutical company developing and manufacturing pharmaceutical and nutraceutical solutions.
sofgenpharma.comCrawled Nov 9, 2026
Sofgen Pharma develops and manufactures pharmaceutical and nutraceutical products. The company operates in 13 countries, including Bolivia, Brazil, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Peru, and the United States, with customers in over 50 countries.
Sofgen Pharma offers full-service contract development and manufacturing for pharmaceutical and nutraceutical products, including softgel manufacturing.
Procaps Group rebrands to **Sofgen Pharma** after receiving shareholder approval. The company operates in pharmaceutical development and manufacturing. The rebrand reflects a strategic shift in identity and market positioning.
Procaps Group S.A. officially rebrands to Sofgen Pharma S.A., reflecting a strategic shift in its pharmaceutical-focused operations. The company specializes in drug delivery technologies and excipients for the pharmaceutical industry. The name change aligns with its expanded portfolio in pharmaceutical solutions.
Procaps Group secures **$130 million in new capital** while restructuring debt to strengthen its financial position. The funding supports operational expansion and liquidity amid restructuring efforts. The announcement highlights a strategic move to stabilize the company’s balance sheet.
Procaps Group raises **$130 million in equity funding** while restructuring debt, with new investors assuming strategic leadership. The company relocates its headquarters to **Bogotá**, signaling a shift toward growth and operational transformation under strengthened governance. This restructuring follows a period of financial restructuring and positions Procaps for expanded execution capabilities.
Procaps Group restructures its Board committees and updates executive leadership following its recent Shareholders Meeting and Board of Directors meeting. The company, a leading LatAm healthcare and pharmaceutical services provider, also announces changes to its Board composition. These decisions aim to enhance governance and operational efficiency.
Procaps Group risks Nasdaq delisting due to a delayed regulatory filing. The company has not submitted required documents within the Nasdaq’s specified timeline, putting its continued listing at risk. Investors and stakeholders are closely monitoring the situation as compliance deadlines loom.
Procaps Group acquires Mexican pharmaceutical manufacturer **Grupo Somar** to strengthen its presence in Latin America. The move follows the company’s 2023 IPO and aligns with its strategy to grow as a leading regional pharma player. Procaps now consolidates its footprint in Mexico, a key market for its drug delivery and formulation services.